VANI Institutional Investor Snapshot (43 Funds)

Vivani Medical (VANI) disclosed that its CEO, Dr. Adam Mendelsohn, presented at the Emerging Growth Conference on July 15, 2026, using a slide deck that updated the expected timeline for the first dosing of its obesity drug candidate SLIM-1 to August 2026. The slides were attached to this 8-K filing as an exhibit under Regulation FD, meaning the information is furnished but not formally filed with the SEC.

Vivani Medical (VANI) signed a definitive merger agreement under which its subsidiary Cortigent will merge into ClearOne, a Nasdaq-listed company. Vivani will receive 12.5 million ClearOne shares in exchange. ClearOne also plans to raise $10 million to $15 million by selling units of common stock and warrants. The deal requires approvals from both companies' stockholders, ClearOne's Nasdaq listing to remain intact, and the financing to close. After the merger, Vivani will appoint four of the five board members of the combined company.

Vivani Medical (VANI) shareholders approved an amended 2022 Omnibus Incentive Plan at the annual meeting. The key change expands the share pool for employee and executive compensation from roughly 10 million shares to over 21 million shares. This gives the company much more equity to use for incentives.